Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Waste Water Reveals Drug Secrets

By Drug Discovery Trends Editor | March 14, 2016

Methamphetamine consumption increased 4.8 times in the metropolitan area over the timeframe. Source: University of QueenslandMethamphetamine residue found in the wastewater of a Queensland city has multiplied five times since 2009.

University of Queensland scientists from The National Research Centre for Environmental Toxicology(Entox) worked with Professor Wayne Hall of the Centre for Youth Substance Abuse Research to obtain the results.

“More than 1000 samples were taken from a coastal metropolitan city and a major inland regional city between 2009 and 2015,” Professor Hall said.

“Methamphetamine consumption increased 4.8 times in the metropolitan area over the timeframe, and 3.4 times in the regional area.

“This coincides with a study released last week, which showed an upsurge of more than 170,000 regular meth users across Australia between 2009 and 2015, to a total of 270,000 users nationwide.”

Professor Jochen Mueller of Entox and colleagues Dr Phong Thai, Ms Foon Yin Lai and Mr Jake O’Brien collaborated to build on previous insightful studies featuring waste testing.

Armed with knowledge about the ways that specific drugs are excreted, they used census populations for both the metropolitan and regional catchments to ascertain their results.

Methamphetamine consumption was measured in milligrams per day per 1000 inhabitants.

In 2009 the mean for the coastal metropolitan area was 234mg/day/1000 people, which increased to 1126mg/day/1000 people in 2015.

The study began a year later in the inland regional city, marked by a mean of 115mg/day/1000 people in 2010, which increased to 398mg/day/1000 people in 2015.

Professor Hall said the wastewater analysis alone did not determine whether consumption had increased because there were more users or because existing users were consuming more.

“However, when you view this together with other timely research, it is consistent with there being exponential growth in the number of users,” Professor Hall said.


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50